Ischemic stroke (IS) is one of the leading causes of death and neurological disability worldwide. Despite the significant burden of IS, recombinant tissue plasminogen activator (rt-PA/alteplase [Genentech’s Activase, other brands]) is the only pharmacological therapy approved for the (acute) treatment of IS owing to persistent failure of investigational compounds over the past two decades. However, because of strict inclusion criteria and documented safety risks, only a small fraction of diagnosed IS events receive rt-PA. Therefore, a tremendous amount of unmet clinical need remains for alternative treatments that can help avert permanent neurological damage and restore neurological function in post-stroke survivors living with residual impairment.
- What percentage of IS patients arrive at the hospital within key time windows for acute drug and/or device intervention?
- How is IS currently managed? What drugs, diagnostics, and devices are used to treat IS, and what are their advantages and disadvantages?
- What are the key areas of unmet need and opportunity in IS? What are the key drivers and limiters of the therapy market?
- What promising agents are advancing through the IS pipeline? How might treatment change with the introduction of novel products? What companies are most vested in developing innovative therapies for IS?
- What is the clinical and commercial potential of late-phase pipeline products in development for the acute and post-acute phase treatment of IS, and what will be their likely positioning should they come to market?
Geography: United States
Primary Research: 3 KOL interviews in April 2020
Key Companies Covered: Genentech / Roche, Boehringer Ingelheim, Mitsubishi Tanabe Pharma, Biogen, Genervon, Athersys, ZZ Biotech, SanBio, Lumosa Therapeutics, ReNeuron, Stemedica Cell Technologies, NoNO
Key Drugs Covered: rt-PA/alteplase (Activase/Actilyse, other brands), edaravone (Radicut, generics), citicoline (Somazina, generics), tenecteplase, glibenclamide, 3K3A-APC, GM602, MultiStem, SB 623, LT 3001, ReN-001, NA-1
Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.
- Ischemic Stroke - Executive Insights - Executive Insights (US)
- Executive Insights - 2020 - Ischemic Stroke
Author(s): Natalie Taylor, PhD
Natalie Taylor, Ph.D. is a Principal Business Insights Analyst with the central nervous system/ophthalmology disorders team at Decision Resources Group. She has over ten years of experience authoring primary and market research reports for pharmaceutical industry clients across multiple psychiatry, pain, neurology, and ophthalmology therapy areas.
Prior to joining DRG, Dr. Taylor worked at QuintilesIMS as manager of the central nervous system portfolio of Disease Insights market forecasting offerings. She completed her Ph.D. in Physiology at Dartmouth College in Hanover, New Hampshire, where she studied the role of serotonergic neurons in the medullary raphe on modulating respiratory responses in mammals. She holds a B.S. in Biology from Dickinson College in Carlisle, Pennsylvania.